These risks may include, but are not limited to the risk factors set forth under the heading Risk Factors in Syneron’s annual report on Form 20-F filed with the SEC. These factors are updated from time to time through the filing of reports and registration statements with the Securities and Exchange Commission.

These statements are only predictions and Syneron cannot guarantee that they will in fact occur. The company does not assure any obligation to update the forward-looking statements discussed in today’s conference call

Finally, this presentation includes non-GAAP financial measures. Syneron provides reconciliation information at the end of the third quarter results press release on the Investor Relations page at

Speaking on the call today are Syneron’s CEO, Lou Scafuri; and Syneron’s CFO, Asaf Alperovitz. Shimon Eckhouse, Syneron’s Chairman of the Board is also on the call and will be available for questions during the Q&A portion at the conclusion of management’s prepared remarks.

Now, I’d like to turn the call over to Lou.

Lou Scafuri

Thank you, Zack. And welcome to Syneron’s third quarter 2011 conference call. During the third quarter we continued to execute on our strategic growth and profitability initiatives further positioning Syneron for ongoing industry leadership.

We achieved several important milestones including the settlement of Syneron and Candela’s patent litigation with Palomar and setting the stage to the launch of two exciting next generation products.

We also demonstrated progress in the PAD segment and continued to invest in the growth of our emerging business units. Together it was another strong quarter that is indicative of our momentum in the marketplace and highlights the success of the company’s strategic vision.

I’ll begin today’s call with a quick overview of our financial results followed by a review of our operational progress. Total revenue in the third quarter 2011 was $57 million, up 28% over the prior year. This represents our fifth consecutive quarter of double-digit year-over-year sales growth and an acceleration of our growth rate from the second quarter 2011.

If you liked this article you might like

4 Stocks Spiking on Big Volume: Ryanair, Trex and More

Syneron Medical (ELOS) Stock Spikes Today on Strong Fourth Quarter Guidance

4 Stocks Under $10 Making Big Moves Higher

5 Stocks Under $10 Making Big Moves

Syneron Medical Ltd. Stock Upgraded (ELOS)